Anti-TNF-α therapies: they are all the same (aren't they?)

S Mpofu, F Fatima, RJ Moots - Rheumatology, 2005 - academic.oup.com
The development of anti-tumour necrosis factor (TNF-) therapy has been a milestone in the
treatment of rheumatoid arthritis (RA) and is proving equally important in other inflammatory-…

[HTML][HTML] Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis

…, R Martin, M Andersson, S Mpofu… - New England journal …, 2015 - Mass Medical Soc
Background Secukinumab is an anti–interleukin-17A monoclonal antibody that has been
shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two …

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled …

…, H Richards, L Pricop, G Ligozio, M Patekar, S Mpofu - The Lancet, 2015 - thelancet.com
Background Interleukin 17A is a proinflammatory cytokine that is implicated in the pathogenesis
of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous secukinumab, …

[HTML][HTML] Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis

…, L Pricop, J Yuan, HB Richards, S Mpofu - … England Journal of …, 2015 - Mass Medical Soc
Background In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs
and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of …

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

…, H Kellner, T Ikawa, S Hugot, S Mpofu - Annals of the …, 2013 - ard.bmj.com
… If you wish to reuse any or all of this article please use the link below which will take you to
the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and …

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE …

…, D van der Heijde, R Landewé, S Mpofu… - Annals of the …, 2018 - ard.bmj.com
… the study and one case of Crohn’s disease in a patient with a history of colitis. There was
one mild, non-serious exacerbation of Crohn’s disease in a secukinumab-treated patient who …

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

…, P Emery, A Readie, R Martin, S Mpofu… - Annals of the …, 2017 - ard.bmj.com
… If you wish to reuse any or all of this article please use the link below which will take you to
the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and …

Cattle manure effects on structural stability and water retention capacity of a granitic sandy soil in Zimbabwe

J Nyamangara, J Gotosa, SE Mpofu - Soil and Tillage Research, 2001 - Elsevier
The evaluation of soil aggregate stability and water retention is important in the assessment
of soil management options. A 3-year study was conducted in 1999 to determine the effects …

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

…, AB Gottlieb, R Martin, K Ding, P Pellet, S Mpofu… - The Lancet, 2020 - thelancet.com
Background Head-to-head trials in psoriatic arthritis are helpful in guiding clinical decision
making. The EXCEED study evaluated the efficacy and safety of secukinumab versus …

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study

…, R Kajekar, EM Delicha, L Pricop, S Mpofu - …, 2017 - academic.oup.com
… of ACR20 response at week 24 with Fisher’s exact test and about 80% power for secondary
… Results are given in mean (s.d.) or least squares mean (s.e.), as appropriate. Evaluations of …